Show results for
Refine by
Schizophrenia Treatment Suppliers & Manufacturers
6 companies found
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
based inDublin 4, IRELAND
Alkermes is focused on developing innovative medicines that aim to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated global biopharmaceutical company, we apply our scientific expertise and ...
Risperdal Consta (risperidone) is a benzisoxazole derivative with potent combined serotonin 5HT2A and dopamine D2 receptor-blocking properties. It is an effective atypical antipsychotic that is well tolerated, based on extensive clinical experience ...
based inRye Brook, NEW YORK (USA)
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is ...
More than 1% of the US adult population is affected by schizophrenia, with symptoms falling into three categories: positive (hallucinations and delusions), negative (flat affect, difficulty in social interactions) and cognitive ...
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
Schizophrenia is a chronic disease that manifests through disturbances of perception, thought, cognition, emotion, motivation and motor activity. Over a lifetime, about 1% of the population will develop ...
based inGeneva, SWITZERLAND
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric ...
We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis. Schizophrenia ...
based inPrinceton, NEW JERSEY (USA)
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative products, with a focus ...
After it is swallowed, ABILIFY MYCITE® (aripiprazole tablets with sensor) sends a tiny signal to a wearable Bluetooth®* patch that connects with your smartphone, allowing you to see your daily data all in one ...